Male-pattern hair loss (androgenetic alopecia)
ICD-10 L64.9
- ~0%
- men affected by age 50
- ~0%
- men affected by age 70
- 0%
- of finasteride users see slowing or regrowth
- ~0%
- of minoxidil users see meaningful regrowth
What is male-pattern hair loss (androgenetic alopecia)?
Male-pattern hair loss (androgenetic alopecia) is the most common form of hair loss in men, affecting ~50% by age 50 and ~80% by age 70. Caused by genetic sensitivity of scalp hair follicles to dihydrotestosterone (DHT), leading to progressive follicular miniaturization. Pattern follows the Norwood-Hamilton scale (I-VII).
What are the symptoms of male-pattern hair loss (androgenetic alopecia)?
- Receding hairline at the temples (typically the earliest sign)
- Thinning at the crown (vertex) — often noticed when seeing photos taken from behind
- Gradually finer, shorter hairs in the affected areas (miniaturization)
- More hair shed when washing or styling (but heavy shedding can also signal telogen effluvium — different condition)
- Hair feels finer overall, even where coverage looks intact
Who is at risk for male-pattern hair loss (androgenetic alopecia)?
- Family history of hair loss on either side (genetic component is dominant)
- Age — risk increases each decade after 20
- Ethnicity — highest in men of European descent, lowest in East Asian and Native American populations
- Underlying conditions: PCOS in women, thyroid disease, iron deficiency can accelerate or mimic
- Smoking (associated with severity in observational studies)
- Stress (telogen effluvium overlay on baseline pattern hair loss)
How is male-pattern hair loss (androgenetic alopecia) diagnosed?
Clinical, by Norwood-Hamilton pattern assessment. Trichoscopy can identify miniaturized hairs. Lab workup typically unnecessary unless atypical pattern, rapid onset, or systemic symptoms suggest secondary cause (thyroid disease, iron deficiency, telogen effluvium).
How is male-pattern hair loss (androgenetic alopecia) treated?
Three FDA-approved treatments with evidence: oral finasteride 1 mg daily (1997 approval), topical minoxidil 2-5% twice daily (1988), and oral minoxidil low-dose (off-label, increasingly used). Dutasteride 0.5 mg (off-label in US) has greater DHT suppression. Hair transplantation for established loss. Earlier intervention is more effective than reactive treatment.
Medications used for male-pattern hair loss (androgenetic alopecia)
Finasteride (Propecia)
finasteride · FDA 1997
Oral DHT blocker. Standard of care for male-pattern hair loss. ~80% slow shedding, ~60% regrow.
Rogaine (topical) / generic oral
minoxidil · FDA 1988
Vasodilator that promotes hair regrowth. Topical OTC; low-dose oral via prescription.
Avodart
dutasteride · FDA 2001
Stronger DHT blocker than finasteride. Off-label for hair loss. Higher effect, smaller evidence base.
Authority reference: www.aad.org
Other conditions
Obesity
Obesity is a chronic disease defined by excess body fat that increases the risk of cardiovascular disease, type 2 diabetes, and other comorb
glp1Type 2 diabetes
Type 2 diabetes (T2D) is a chronic metabolic disease characterized by insulin resistance and progressive beta-cell dysfunction, resulting in
glp1Chronic kidney disease (CKD)
Chronic kidney disease is progressive loss of kidney function over months to years. Classified by estimated glomerular filtration rate (eGFR
glp1Metabolic dysfunction-associated steatohepatitis (MASH)
MASH (formerly NASH) is the inflammatory form of metabolic dysfunction-associated fatty liver disease (MASLD). Characterized by hepatic stea
edErectile dysfunction
Erectile dysfunction (ED) is the persistent inability to attain or maintain an erection sufficient for satisfactory sexual performance. Prev
skincareAcne vulgaris
Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit, characterized by comedones, papules, pustules, and (in severe cas
mental healthMajor depressive disorder
Major depressive disorder (MDD) is a chronic, recurrent mood disorder characterized by persistent low mood, loss of interest or pleasure (an
anxietyGeneralized anxiety disorder
Generalized anxiety disorder (GAD) is excessive, uncontrollable worry about everyday matters lasting ≥6 months, with at least 3 associated s
Related topics
Sources
Primary sources cited above. FDA labeling, peer-reviewed trials, and specialty-society guidelines only.
- Finasteride in the Treatment of Men with Androgenetic Alopecia (5-year extension) · Journal of the American Academy of Dermatology, 2002 · PMID 11907492
- Causes of Hair Loss in Men · American Academy of Dermatology, 2024
- Low-dose Oral Minoxidil for Treatment of Androgenetic Alopecia: A Systematic Review · JAMA Dermatology, 2021 · PMID 33502467
People also ask
Does finasteride really work?
Yes. The pivotal 5-year trial showed 65% of men on finasteride 1 mg/day had stable hair counts or regrowth, compared to 0% on placebo. The earlier you start, the more hair you preserve — finasteride prevents miniaturization but can't fully reverse advanced loss.
What's the difference between finasteride and dutasteride?
Both block the enzyme that converts testosterone to DHT. Finasteride targets type II 5-alpha-reductase; dutasteride blocks both type I and II and produces ~90% DHT reduction vs ~70% for finasteride. Dutasteride is FDA-approved for benign prostatic hyperplasia, not hair loss, but is prescribed off-label for AGA.
Can I stop finasteride once my hair has stabilized?
No. Discontinuation typically returns scalp DHT to baseline within weeks and miniaturization resumes. Hair gains from finasteride are maintained only as long as treatment continues. The same applies to minoxidil — stop the drug, lose the gains over 3-12 months.
Are oral and topical minoxidil equally effective?
Off-label low-dose oral minoxidil (typically 1.25-5 mg daily) is increasingly used and produces comparable or superior regrowth in observational comparisons. Topical minoxidil is the FDA-approved form; the oral path is dermatologist-prescribed off-label with attention to systemic effects (peripheral edema, hair growth elsewhere).